‘Pay For Delay’ Drug Accords Get U.S. Supreme Court’s Scrutiny

‘Pay For Delay’ Drug Accords Get U.S. Supreme Court’s Scrutiny

Daniel Acker/Bloomberg

The FTC, backed by the Justice Department, is appealing a ruling that rejected its suit against Solvay Pharmaceuticals Inc., now owned by Abbott Labs, and three generic-drug makers over Androgel, a treatment for low testosterone in men.